HOME >> MEDICINE >> NEWS
Where do new therapies work best?

An observational study to investigate how new therapies for rheumatic diseases perform across different conditions has revealed that they may be more successful in certain conditions. The data is presented today at the Annual European Congress of Rheumatology in Amsterdam, the Netherlands. An increasing proportion of patients with rheumatic conditions such as ankylosing spondylitis (AS), psoriatic arthritis (PsA) and rheumatoid arthritis (RA) now receive anti-TNF treatment a newer group of drugs which are used to reduce inflammation and manage disease activity*. Study lead Dr Marte Heiberg, of the Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, told delegates: "Many studies have focused on efficacy of these drugs, however less is known about comparative real life performance of these drugs across different diagnostic groups".

The study was conducted across 5 Norwegian Rheumatology Departments and included 796 RA patients, 162 PsA patients and 211 patients with a diagnosis of AS. All patients were on an anti-TNF treatment regimen of infliximab, etanercept or adalimumab +/- methotrexate (MTX). The primary outcome was the number of patients still on therapy at one year known as the adherence to therapy. RA was used as the reference group and within each diagnostic group the adherence to anti-TNF monotherapy versus TNF+MTX was compared.

The relative risk for withdrawal from TNF+MTX versus anti-TNF monotherapy was 0.54 for RA patients, 0.49 for PsA patients and 0.83 for AS patients, demonstrating that combination treatment strategy of anti-TNF+MTX worked better than anti-TNF monotherapy in patients with RA and PsA. Although the crude one-year overall drug adherence rates for anti-TNF therapy were superior in patients with PsA and AS compared to RA, after adjusting for age, gender and concomitant MTX, the adherence to anti-TNF treatment were similar in patients with RA and PsA whereas the adherence to anti-TNF treatment was superior in patients
'"/>

Contact: Mia Gannedahl
mia_gannedahl@uk.cohnwolfe.com
44-207-331-2325
European League Against Rheumatism
22-Jun-2006


Page: 1 2

Related medicine news :

1. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
2. Where is the most dangerous place to travel over the holiday?
3. Where should I have my outpatient surgery?
4. Where are medical graduates practising and why?
5. Where the brain organizes actions
6. Where we change our mind
7. Where your brain wires itself to like (name your favorite brand)
8. Where lifes memories are stored
9. Future therapies for stroke may block cell death
10. Antifolate therapies found effective against certain type of malaria
11. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Where new therapies work best

(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the ... , Purchasing an accidental death and dismemberment rider for ... of rider provides benefits if the insured dies in an ... form of life insurance. , AD&D is not expensive ...
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance of ... the costs of an auto insurance policy . , Clients ... prices for their vehicle insurance policies. The safety a vehicle offers ... Because of this, drivers should always carry a first aid ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
(Date:1/23/2015)... MYERS, Fla. , Jan. 23, 2015  Today the ... of Novartis, Bexsero® for the prevention of serogroup ... 25. Bexsero and Pfizer,s vaccine Trumenba®, which received FDA ... helping prevent this devastating disease. "I ...
(Date:1/23/2015)... WASHINGTON , Jan. 23, 2015  A new analysis ... Part D 2015 enrollment data shows that 81 percent ... convenient access and extra discounts at certain pharmacies. The ... "Preferred pharmacy plans are now the foundation of ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
Cached News: